| Delavirdine (Rescriptor) | None | Rash, increased transaminase levels, headache | Dihydroergotamine mesylate (DHE 45), ergotamine (Ergostat), H2-receptor antagonists, lovastatin (Mevacor), midazolam (Versed), proton pump inhibitors, rifabutin (Mycobutin), rifampin (Rifadin), simvastatin (Zocor), triazolam (Halcion), St. John's wort | Take without regard to meals. | May increase levels of dapsone, warfarin (Coumadin), and quinidine. May increase levels of sildenafil (Viagra) and adverse effects; do not exceed 25 mg in a 48-hour period. |
| Efavirenz (Sustiva) | None | Rash, central nervous system symptoms, psychiatric symptoms, increased transaminase levels, hepatotoxicity, false-positive results from cannabinoid tests; teratogenic in monkeys | Dihydroergotamine mesylate, ergotamine, midazolam, triazolam, St. John's wort | Take before or after meals; high-fat/high-calorie meals increase peak plasma concentrations of capsules by 39% and tablets by 79%. | Increases levels of ethinyl estradiol by 37%; use alternate method of contraception. |
| Nevirapine (Viramune) | Severe hepatotoxicity including fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure; skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions have been reported. | Rash and hepatitis, including hepatic necrosis | St. John's wort | Take without regard to meals. | May decrease levels of ethinyl estradiol by approximately 20%; use alternate method of contraception. |
| Patients should be monitored intensively during the first 12 weeks of therapy for hepatotoxicity or skin reactions; a 14-day lead-in period must be followed strictly. Nevirapine should not be restarted after severe hepatic, skin, or hypersensitivity reactions. | | | | |